MX2019010707A - Metodos para tratar y/o prevenir queratosis actinica. - Google Patents

Metodos para tratar y/o prevenir queratosis actinica.

Info

Publication number
MX2019010707A
MX2019010707A MX2019010707A MX2019010707A MX2019010707A MX 2019010707 A MX2019010707 A MX 2019010707A MX 2019010707 A MX2019010707 A MX 2019010707A MX 2019010707 A MX2019010707 A MX 2019010707A MX 2019010707 A MX2019010707 A MX 2019010707A
Authority
MX
Mexico
Prior art keywords
treating
methods
actinic keratosis
preventing actinic
preventing
Prior art date
Application number
MX2019010707A
Other languages
English (en)
Inventor
Fun Rudolf Kwan Min-
Yiu - Nam LAU Johnson
Douglas Kramer E
Lawrence Cutler David
Fang Jane
Original Assignee
Athenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex Inc filed Critical Athenex Inc
Publication of MX2019010707A publication Critical patent/MX2019010707A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La solicitud pertenece a métodos para tratar y/o prevenir queratosis actínica, que comprende administrar una cantidad terapéuticamente efectiva de KX-01, (ver fórmula I) (I), a un sujeto que lo necesita.
MX2019010707A 2017-03-10 2018-03-12 Metodos para tratar y/o prevenir queratosis actinica. MX2019010707A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (1)

Publication Number Publication Date
MX2019010707A true MX2019010707A (es) 2020-01-15

Family

ID=63446658

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010707A MX2019010707A (es) 2017-03-10 2018-03-12 Metodos para tratar y/o prevenir queratosis actinica.
MX2021013354A MX2021013354A (es) 2017-03-10 2019-09-09 Metodos para tratar y/o prevenir queratosis actinica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013354A MX2021013354A (es) 2017-03-10 2019-09-09 Metodos para tratar y/o prevenir queratosis actinica.

Country Status (13)

Country Link
US (3) US10617693B2 (es)
EP (1) EP3592355A4 (es)
JP (2) JP7502863B2 (es)
KR (2) KR20240090837A (es)
CN (1) CN110891575A (es)
AU (2) AU2018231144B2 (es)
BR (1) BR112019018687A2 (es)
CA (1) CA3055938A1 (es)
IL (1) IL269182B2 (es)
MX (2) MX2019010707A (es)
TW (1) TWI841523B (es)
WO (1) WO2018165647A1 (es)
ZA (1) ZA202100106B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CA3055938A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
AU2019231706A1 (en) * 2018-03-07 2020-09-24 Atnx Spv, Llc Compositions and methods for treating hyperproliferative skin disorders
JP2022535267A (ja) * 2019-06-05 2022-08-05 アセネックス インコーポレイテッド 乾癬を治療および／または予防する方法
EP4263833A1 (en) * 2021-01-21 2023-10-25 Sirnaomics, Inc. Compositions and methods for treatment of skin cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE544748T1 (de) 2004-12-28 2012-02-15 Kinex Pharmaceuticals Llc Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CA2656564C (en) 2006-06-29 2015-06-16 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
CA2686267C (en) 2007-05-17 2015-10-06 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
EP2378876B1 (en) * 2008-12-19 2018-11-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CA3055938A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
US20230172942A1 (en) 2023-06-08
AU2024201828A1 (en) 2024-05-02
TWI841523B (zh) 2024-05-11
IL269182A (en) 2019-11-28
AU2018231144B2 (en) 2023-12-21
ZA202100106B (en) 2022-08-31
IL269182B2 (en) 2023-11-01
EP3592355A4 (en) 2021-01-06
BR112019018687A2 (pt) 2020-04-07
JP2020510042A (ja) 2020-04-02
EP3592355A1 (en) 2020-01-15
TW201842913A (zh) 2018-12-16
US10617693B2 (en) 2020-04-14
JP2023015269A (ja) 2023-01-31
RU2019131757A (ru) 2021-04-12
CA3055938A1 (en) 2018-09-13
MX2021013354A (es) 2021-11-18
JP7502863B2 (ja) 2024-06-19
IL269182B1 (en) 2023-07-01
US20200197405A1 (en) 2020-06-25
RU2019131757A3 (es) 2021-05-31
KR20240090837A (ko) 2024-06-21
AU2018231144A1 (en) 2019-10-03
US20180256589A1 (en) 2018-09-13
WO2018165647A1 (en) 2018-09-13
US11497750B2 (en) 2022-11-15
KR20190141661A (ko) 2019-12-24

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
WO2017059319A3 (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
PH12020550936A1 (en) Combination drug including tlr7 agonist
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
SG10201909413SA (en) Method of treating medulloblastoma with an ezh2 inhibitor
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
WO2015112902A3 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2019000677A (es) Células miméticas de células b.
MX2018014621A (es) Composicion biopesticida para uso en la prevencion o para minimizar la enfermedad de la planta.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
FR3045392B1 (fr) Dispositif pour le traitement d'un sujet par combinaison notamment de la lithotherapie, la chromotherapie, la luminotherapie et la musicotherapie
WO2015134603A3 (en) Methods for treating cancer